Search Results - "Neelapu SS"

Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.

Authors: Gribben JG Palomba ML Limbrick-Oldfield E et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2026 Apr; Vol. 67 (5), pp. 1184-1188. Date of Electronic Publication: 2025 Dec 30.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE; In Process

Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].

Authors: Hines MR Knight TE McNerney KO et al.

Source: Transplantation and cellular therapy [Transplant Cell Ther] 2026 Jun; Vol. 32 (6), pp. 765-766. Date of Electronic Publication: 2025 Oct 30.

Publication Type: Published Erratum

Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE; In Process

Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.

Authors: Irajizad E Fahrmann JF Katayama H et al.

Source: MedRxiv : the preprint server for health sciences [medRxiv] 2026 May 02. Date of Electronic Publication: 2026 May 02.

Publication Type: Journal Article; Preprint

Journal Info: Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.

Authors: Strati P Feng L Westin JR et al.

Source: Nature communications [Nat Commun] 2025 Aug 07; Vol. 16 (1), pp. 7300. Date of Electronic Publication: 2025 Aug 07.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma.

Authors: Kim K Shah R Ayers A et al.

Source: British journal of haematology [Br J Haematol] 2026 Mar; Vol. 208 (3), pp. 992-1000. Date of Electronic Publication: 2026 Jan 11.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.

Authors: Yang H Arita K Bowman K et al.

Source: BioRxiv : the preprint server for biology [bioRxiv] 2026 Jan 20. Date of Electronic Publication: 2026 Jan 20.

Publication Type: Journal Article; Preprint

Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.

Authors: Manzar GS Pinnix CC Dudzinski SO et al.

Source: Frontiers in immunology [Front Immunol] 2025 Jan 31; Vol. 16, pp. 1517348. Date of Electronic Publication: 2025 Jan 31 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.

Authors: Neelapu SS Chavez JC Sehgal AR et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Nov 20; Vol. 43 (33), pp. 3573-3577. Date of Electronic Publication: 2025 Oct 16.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies.

Authors: Locke FL Nikiforow S Frigault MJ et al.

Source: Transplantation and cellular therapy [Transplant Cell Ther] 2025 Nov 07. Date of Electronic Publication: 2025 Nov 07.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy.

Authors: Strati P Brandt A Lionel AC et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Oct 09; Vol. 13 (10). Date of Electronic Publication: 2025 Oct 09.

Publication Type: Journal Article

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma.

Authors: Strati P Feng L Tyshevich A et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Oct 01; Vol. 31 (19), pp. 4079-4088.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.

Authors: Kim ST Chu Y Misoi M et al.

Source: Nature communications [Nat Commun] 2024 Jul 04; Vol. 15 (1), pp. 5621. Date of Electronic Publication: 2024 Jul 04.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE

Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.

Authors: Oluwole OO Neelapu SS Ray MD et al.

Source: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jun; Vol. 24 (6), pp. 457-465. Date of Electronic Publication: 2024 Apr 24.

Publication Type: Journal Article; Systematic Review; Network Meta-Analysis

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.

Authors: Lionel AC Gurumurthi A Fetooh A et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2024 May; Vol. 65 (5), pp. 669-673. Date of Electronic Publication: 2024 Jan 22.

Publication Type: Letter; Case Reports

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.

Authors: Lunning MA Wang HL Hu ZH et al.

Source: American journal of hematology [Am J Hematol] 2024 May; Vol. 99 (5), pp. 880-889. Date of Electronic Publication: 2024 Mar 19.

Publication Type: Observational Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma.

Authors: Akkad N Feng L Westin JR et al.

Source: Blood advances [Blood Adv] 2025 Sep 09; Vol. 9 (17), pp. 4396-4404.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching.

Authors: Locke FL Le Gall JB Fisher PW et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Sep; Vol. 43 (25), pp. 2834-2835. Date of Electronic Publication: 2025 Jun 23.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE; In Process

Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma.

Authors: Poddar S Yan J Tiwari G et al.

Source: The Journal of clinical investigation [J Clin Invest] 2025 Aug 15; Vol. 135 (16). Date of Electronic Publication: 2025 Aug 15 (Print Publication: 2025).

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: eCollection Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.

Authors: Saha S Rehman L Rehman A et al.

Source: Blood advances [Blood Adv] 2025 Jul 22; Vol. 9 (14), pp. 3429-3440.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.

Authors: Gopal AK Armand P Neelapu SS et al.

Source: Blood advances [Blood Adv] 2025 Jul 08; Vol. 9 (13), pp. 3383-3394.

Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase I; Clinical Trial, Phase II

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE